Torrent Pharmaceuticals Ltd. - Research Center
500420 TORNTPHARM Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Sales | 4,267.00 | 3,861.00 | 3,248.00 | 3,494.00 | 3,367.00 |
| Operating profit | 1,473.00 | 1,285.00 | 905.00 | 1,195.00 | 1,196.00 |
| Interest | 167.00 | 113.00 | 106.00 | 130.00 | 183.00 |
| Gross profit | 1,332.00 | 1,212.00 | 899.00 | 1,169.00 | 1,029.00 |
| EPS (Rs) | 19.20 | 17.70 | 23.10 | 35.45 | 34.33 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Other income | 26.00 | 40.00 | 100.00 | 104.00 | 16.00 |
| Stock adjustment | -86.00 | 98.00 | -18.00 | - | -66.00 |
| Raw material | 867.00 | 740.00 | 757.00 | 772.00 | 716.00 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 735.00 | 615.00 | 535.00 | 563.00 | 562.00 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,278.00 | 1,123.00 | 1,069.00 | 964.00 | 959.00 |
| Provisions made | - | - | - | - | - |
| Depreciation | 375.00 | 305.00 | 299.00 | 303.00 | 303.00 |
| Taxation | 307.00 | 308.00 | 209.00 | 266.00 | 145.00 |
| Net profit / loss | 650.00 | 599.00 | 391.00 | 600.00 | 581.00 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 169.23 | 169.23 | 84.62 | 84.62 | 84.62 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 34.52 | 33.28 | 27.86 | 34.20 | 35.52 |
| GPM (%) | 31.03 | 31.07 | 26.85 | 32.49 | 30.42 |
| NPM (%) | 15.14 | 15.36 | 11.68 | 16.68 | 17.17 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis